CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study.
Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 相关神经毒性的表现常包括书写改变、震颤和轻度意识混乱状态,尤其是在其发生早期。
免疫效应细胞相关神经毒性综合征(ICANS)是CAR-T 细胞治疗的重要并发症。本研究旨在确定澳大利亚一家三级转诊中心ICANS患者的神经毒性表现模式。
本单中心前瞻性队列研究连续纳入所有因符合条件的血液系统恶性肿瘤接受CAR-T 治疗的患者。所有患者均在CAR-T 输注前、ICANS发生期间及治疗1个月后接受全面神经系统评估和认知筛查。评估基线人口学特征、发生率、神经毒性模式及管理情况。
在19个月期间,53例符合条件患者中有12例(23%)发生神经毒性,其中10/12例(83%)为1级。所有患者最初均出现书写变化和震颤。多数患者表现出认知变化;与免疫效应细胞相关脑病评分相比,蒙特利尔认知评估评分下降更明显。所有神经毒性表现均持续时间较短,并在1个月内缓解;平均持续8.2天(范围1–33天)。
CAR-T 相关神经毒性常表现为书写改变、震颤和轻度意识混乱,尤其发生于早期阶段。常规神经系统监测可能无法发现这些表现。它们可作为ICANS初现的、易于观察的临床标志。
Over a 19-month period, 23% (12) of the 53 eligible patients developed neurotoxicity (10/12 [83%] being grade 1). All patients showed changes in handwriting and tremor as their initial presentation. Changes in cognition were manifested in most of the patients, with a more substantial drop noted in their Montreal Cognitive Assessment compared to immune effector cell-associated encephalopathy scores. All manifestations of neurotoxicity were short-lived and resolved within a 1-month period, with a mean duration of 8.2 days (range = 1-33).
The patterns of CAR-T-related neurotoxicity often include change in handwriting, tremor, and mild confusional state, especially early in their evolution. These may remain undetected by routine neurological surveillance. These features represent accessible clinical markers of incipient ICANS.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。